: The Lifecycle Controller (LCC) is currently being accessed by another user or automated process. Recommended Resolutions
The AIO SUP-0108 phase II trial investigated intraperitoneal bevacizumab for treating refractory malignant ascites, but found no significant difference in paracentesis intervals between the treatment and placebo groups. While generally well-tolerated, the study indicated that this targeted therapy did not meet efficacy expectations for reducing ascites in advanced gastrointestinal cancer patients. For a detailed overview of the trial, see the report on ResearchGate . sup0108 top
Field studies comparing TOP-tier components against economy lines show a 300% to 500% longer mean time between failures (MTBF). This translates to fewer shutdowns, lower maintenance costs, and higher overall equipment effectiveness (OEE). : The Lifecycle Controller (LCC) is currently being